BioAge Labs (BIOA) | Stock Overview & Key Data
BioAge Labs Performance Comparison
Stock Range
Today's Range
Low: $5.63
High: $5.94
on October 2, 2025
52 Week Range
Low: $2.88
High: $26.62
on April 9, 2025
on October 22, 2024
All-Time High: $26.62 on October 21, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$212.2M
EPS
-7.38
P/E Ratio (TTM)
-0.89
Forward P/E
-2.08
P/B Ratio
0.72
PEG Ratio
-2.08
Div. Yield
N/A
ROE
-35.88%
Beta
N/A
Debt to Equity
2.97
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-1,026.99%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-23.46%
Return on Equity (TTM)
-35.88%
EBITDA
$-91.1M
Net Income (TTM)
$-79.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.11
Quarterly Revenue Growth (YoY)
66.23%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| BioAge Labs BIOA | 212.23M Micro-cap | 13.03% | 26.88% | 39.15% | 69.05% | 6.12% | -73.05% | -71.90% | -71.90% |
| Haleon Plc - ADR HLN | 41.72B Large-cap | 1.83% | -9.02% | -13.45% | -12.60% | -5.93% | -14.37% | 45.81% | 19.84% |
| United Therapeutics UTHR | 19.33B Large-cap | 4.24% | 9.54% | 50.21% | 42.01% | 23.10% | 24.59% | 114.46% | 326.34% |
| Ironwood IRWD | 230.66M Micro-cap | 26.77% | 22.90% | 117.57% | 11.81% | -62.82% | -62.56% | -84.11% | -84.65% |
| Journey Medical DERM | 186.80M Micro-cap | 5.80% | 2.53% | 3.69% | 16.99% | 82.50% | 11.79% | 208.02% | -26.26% |
| China SXT SXTC | 183.29M Micro-cap | 3.77% | 16.20% | -7.30% | -35.80% | 236.73% | 129.17% | -91.43% | -93.50% |
Ownership & Short Interest
Insider Ownership
3.63%
Institutional Ownership
67.99%
Shares Short
2M
Short Ratio
13.24
Short % of Shares Outstanding
7.66%
Average 10-Day Volume
211K
Average 90-Day Volume
191K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BIOA's 52-week high and low?
- In the last 52 weeks, BioAge Labs reached a high of $26.62 (on October 22, 2024) and a low of $2.88 (on April 9, 2025).
- What is the market cap and P/E ratio for BIOA?
- Curious about BioAge Labs's size and valuation? Its market capitalization stands at 212.23M. When it comes to valuation, the P/E ratio (trailing twelve months) is -0.89, and the forward P/E (looking ahead) is -2.08.
- Does BIOA pay dividends? If so, what's the yield?
- As for dividends, BioAge Labs isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are BioAge Labs's main competitors or similar companies to consider before investing?
When looking at BioAge Labs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Haleon Plc - ADR
HLN41.72B Healthcare Drug Manufacturers - Specialty & Generic -14.37% 45.81% United Therapeutics
UTHR19.33B Healthcare Drug Manufacturers - Specialty & Generic 24.59% 114.46% Ironwood
IRWD230.66M Healthcare Drug Manufacturers - Specialty & Generic -62.56% -84.11% Journey Medical
DERM186.80M Healthcare Drug Manufacturers - Specialty & Generic 11.79% 208.02% China SXT
SXTC183.29M Healthcare Drug Manufacturers - Specialty & Generic 129.17% -91.43% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for BioAge Labs Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of BioAge Labs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -35.88%, the Debt to Equity ratio from the most recent quarter is 2.97, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for BIOA?
- Looking at BioAge Labs's growth, its revenue over the trailing twelve months (TTM) was $4M. Compared to the same quarter last year (YoY), quarterly revenue grew by 66.23%, and quarterly earnings saw a YoY growth of N/A.
- How much of BIOA stock is held by insiders and institutions?
- Wondering who owns BioAge Labs stock? Company insiders (like executives and directors) hold about 3.63% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 67.99%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.